Amarin - The Science Of Lipid Therapy (Seite 156)
eröffnet am 03.01.14 20:10:32 von
neuester Beitrag 04.04.24 15:47:54 von
neuester Beitrag 04.04.24 15:47:54 von
Beiträge: 1.840
ID: 1.190.027
ID: 1.190.027
Aufrufe heute: 0
Gesamt: 156.369
Gesamt: 156.369
Aktive User: 0
ISIN: US0231112063 · WKN: A0NBNG · Symbol: EH3A
0,8601
USD
-2,11 %
-0,0185 USD
Letzter Kurs 02:00:00 Nasdaq
Neuigkeiten
24.04.24 · globenewswire  |
22.04.24 · globenewswire |
15.04.24 · globenewswire |
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 08.04.24 · globenewswire |
06.04.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,000 | +25,00 | |
| 6,0000 | +25,00 | |
| 0,7113 | +21,90 | |
| 0,6400 | +18,52 | |
| 1,0360 | +14,98 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8410 | -17,06 | |
| 9,7200 | -19,60 | |
| 4,0000 | -27,27 | |
| 2,7280 | -29,14 | |
| 14,510 | -32,32 |
Beitrag zu dieser Diskussion schreiben
Feedback
Wieder Kursziel 10 US Dollar:
une 27, 2017 8:25 AM EDT Tweet Share E-mail
Get Alerts AMRN Hot Sheet
Price: $3.49 +1.16%
Rating Summary:
8 Buy, 11 Hold, 0 Sell
Rating Trend: Up Up
Today's Overall Ratings:
Up: 7 | Down: 22 | New: 29
Trade AMRN Now!
Join SI Premium – FREE
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
H.C. Wainwright analyst, Andrew Fein, reiterated his Buy rating on shares of Amarin Corporation (NASDAQ: AMRN) after Novartis (NYSE: NVS) announced a topline win for its Phase 3 CANTOS study evaluating antibody canakinumab in combination with standard of care therapy in reducing cardiovascular risk in people with prior heart attack and inflammatory antherosclerosis. The analyst believes the CANTOS study validates the mechanism and commercial upside to REDUCE-IT.
The analyst stated "we believe NVS’ outcome study supports our bull argument of an asymmetric
risk-reward for Vascepa ahead of REDUCE-IT readout".
No change to the price target of $10.
For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.
Shares of Amarin Corporation closed at $3.45 yesterday.
une 27, 2017 8:25 AM EDT Tweet Share E-mail
Get Alerts AMRN Hot Sheet
Price: $3.49 +1.16%
Rating Summary:
8 Buy, 11 Hold, 0 Sell
Rating Trend: Up Up
Today's Overall Ratings:
Up: 7 | Down: 22 | New: 29
Trade AMRN Now!
Join SI Premium – FREE
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
H.C. Wainwright analyst, Andrew Fein, reiterated his Buy rating on shares of Amarin Corporation (NASDAQ: AMRN) after Novartis (NYSE: NVS) announced a topline win for its Phase 3 CANTOS study evaluating antibody canakinumab in combination with standard of care therapy in reducing cardiovascular risk in people with prior heart attack and inflammatory antherosclerosis. The analyst believes the CANTOS study validates the mechanism and commercial upside to REDUCE-IT.
The analyst stated "we believe NVS’ outcome study supports our bull argument of an asymmetric
risk-reward for Vascepa ahead of REDUCE-IT readout".
No change to the price target of $10.
For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.
Shares of Amarin Corporation closed at $3.45 yesterday.
Updated - June 26, 2017 4:24 PM EDT)
(updated to expand analyst commentary)
Cantor Fitzgerald Assumes coverage on Amarin Corporation (NASDAQ: AMRN) with a Overweight rating and a price target of $10.00.
Analyst Louise Chen sees a greater marketing efforts and positive results from REDUCE-IT study in 2018 that should drive upside to earnings revisions. She believes the revision to reach levels that are not reflected in the consensus estimate currently and therefore sees upside to the stock.
The call appears quiet dramatic as the PT is nearly 3x where the stock is currently trading (PT is $10, stock is trading around $3.56 as of this updated posting).
She says when it comes to REDUCE-IT, less is more. She expect positive results from the outcome of the study which is due mid-2018. She thinks the company will expand its sales force by multiples, from nearly 135 reps currently to somewhere in the range of 400 to 500 reps in the US. She also sees potential for promotional increases to consumers.
Two reason Chen is confident in the company:
The JELIS study tested the effects of long-term use of EPA in addition to a statin in patients with hypercholesterolemia and showed a 19% risk reduction in CV events, and
There are over 40 papers which support the correlation between TGs and CV risk.
Even if REDUCE-IT misses the primary endpoint, which is usually brutal for companies, there is still value according to Chen. To wit: "There are subsets of patients in the study such as diabetics that could find the drug helpful. Diabetics are believed to be at higher risk than people who aren’t diabetic. People who have had prior events are believed to be at higher risk than people who haven't. People who have higher TG baselines are believed to be at higher risk. Importantly, the usage of fibrates continues to be robust despite the fact that fibrates had failed outcome studies."
Furthermore she says Vascepa sales are still underappreciated citing a considerable growth opportunity.
FY 2017 EPS estimate is for a loss of $0.23 and FY 2018 EPS estimate is for a loss of $0.04.
For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.
Shares of Amarin Corporation closed at $3.36 Friday.
(updated to expand analyst commentary)
Cantor Fitzgerald Assumes coverage on Amarin Corporation (NASDAQ: AMRN) with a Overweight rating and a price target of $10.00.
Analyst Louise Chen sees a greater marketing efforts and positive results from REDUCE-IT study in 2018 that should drive upside to earnings revisions. She believes the revision to reach levels that are not reflected in the consensus estimate currently and therefore sees upside to the stock.
The call appears quiet dramatic as the PT is nearly 3x where the stock is currently trading (PT is $10, stock is trading around $3.56 as of this updated posting).
She says when it comes to REDUCE-IT, less is more. She expect positive results from the outcome of the study which is due mid-2018. She thinks the company will expand its sales force by multiples, from nearly 135 reps currently to somewhere in the range of 400 to 500 reps in the US. She also sees potential for promotional increases to consumers.
Two reason Chen is confident in the company:
The JELIS study tested the effects of long-term use of EPA in addition to a statin in patients with hypercholesterolemia and showed a 19% risk reduction in CV events, and
There are over 40 papers which support the correlation between TGs and CV risk.
Even if REDUCE-IT misses the primary endpoint, which is usually brutal for companies, there is still value according to Chen. To wit: "There are subsets of patients in the study such as diabetics that could find the drug helpful. Diabetics are believed to be at higher risk than people who aren’t diabetic. People who have had prior events are believed to be at higher risk than people who haven't. People who have higher TG baselines are believed to be at higher risk. Importantly, the usage of fibrates continues to be robust despite the fact that fibrates had failed outcome studies."
Furthermore she says Vascepa sales are still underappreciated citing a considerable growth opportunity.
FY 2017 EPS estimate is for a loss of $0.23 and FY 2018 EPS estimate is for a loss of $0.04.
For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.
Shares of Amarin Corporation closed at $3.36 Friday.
Trading Spotlight
Neue ATH`s bei den Verschreibungen, schon fast 23.000 pro Woche ohne Reduce IT:
Scripts Update for Week Ending 05/05
ATH in TRx & Refills Numbers and Market Share
V
TRx: 22,736 {vs 21,609; +5.22%} Sector +3.48% -- ATH
NRx: 8,980 {vs 8,602; +4.39%} Sector +2.97% -- (ATH = 9,220)
Ref: 13,756 {vs 13,007; +5.76%} Sector +3.79% -- ATH
Scripts Update for Week Ending 05/05
ATH in TRx & Refills Numbers and Market Share
V
TRx: 22,736 {vs 21,609; +5.22%} Sector +3.48% -- ATH
NRx: 8,980 {vs 8,602; +4.39%} Sector +2.97% -- (ATH = 9,220)
Ref: 13,756 {vs 13,007; +5.76%} Sector +3.79% -- ATH
Neu ATH`s bei den Verschreibungen, jetzt schon über 22.000 pro Woche:
TRx:22,141{vs 20,827;+6.31%}Sec +2.94% ATH
NRx:9,152{vs 8,696;+5.24%}Sec +2.61% ATH=9,220
Ref:12,989{vs 12,131;+7.07%}Sec+3.14% ATH
TRx:22,141{vs 20,827;+6.31%}Sec +2.94% ATH
NRx:9,152{vs 8,696;+5.24%}Sec +2.61% ATH=9,220
Ref:12,989{vs 12,131;+7.07%}Sec+3.14% ATH
Antwort auf Beitrag Nr.: 54.593.091 von lobberland am 22.03.17 21:46:32Ich bin auch seit Herbst mit dabei.
Mal schaun, wann wieder Bewegung reinkommt.
Mal schaun, wann wieder Bewegung reinkommt.
Antwort auf Beitrag Nr.: 54.586.896 von clinton49 am 22.03.17 09:38:57Hi das ist schön 
Prima, dann sind wir zu jetzt dritt 
Ich hoffe wir werden hier noch belohnt für unsere Geduld.
CU
Prima, dann sind wir zu jetzt dritt 
Ich hoffe wir werden hier noch belohnt für unsere Geduld.
CU
Durchsuchen
Amarin - The Science Of Lipid Therapy
